Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

BACKGROUND: Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy. Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin, thus enhancing its cytotoxicity. Studies have not yet investigated the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Chun-Hao, Chang, Ying-Fang, Lee, Ming-Shuo, Wen, B-Chen, Ko, Jen-Chung, Liang, Sheng-Kai, Liang, Mei-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100277/
https://www.ncbi.nlm.nih.gov/pubmed/27821078
http://dx.doi.org/10.1186/s12885-016-2888-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100277/
https://www.ncbi.nlm.nih.gov/pubmed/27821078
http://dx.doi.org/10.1186/s12885-016-2888-7

Ejemplares similares